The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...

Aloft Bangkok-Sukhumvit 11, the first Aloft hotel in Thailand and part of Marriott Bonvoy's portfolio of over 30 ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

The Internal Revenue Code 1 requires corporations to provide information statements to employees (including former employees) and information filings to the IRS regarding exercises of incentive ...

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option. Newron ...

Alvotech and Teva announce filing acceptance of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab) Latest news ...

Alvotech and Teva announce filing acceptance of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab) Latest news ...